ORAQIX Drug Patent Profile

Which patents cover Oraqix, and when can generic versions of Oraqix launch?

Oraqix is a drug marketed by Dentsply Pharm and is included in one NDA.

The generic ingredient in ORAQIX is lidocaine; prilocaine. There are twenty-nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oraqix

A generic version of ORAQIX was approved as lidocaine; prilocaine by FOUGERA PHARMS on August 18^th, 2003.

Summary for ORAQIX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	2
Patent Applications:	307
Drug Prices:	Drug price information for ORAQIX
What excipients (inactive ingredients) are in ORAQIX?	ORAQIX excipients list
DailyMed Link:	ORAQIX at DailyMed

See drug prices for ORAQIX

Recent Clinical Trials for ORAQIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Joanneum Research Forschungsgesellschaft mbH	N/A
Dentsply International	Phase 4

See all ORAQIX clinical trials

US Patents and Regulatory Information for ORAQIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dentsply Pharm	ORAQIX	lidocaine; prilocaine	GEL;PERIODONTAL	021451-001	Dec 19, 2003		RX	Yes	Yes

Expired US Patents for ORAQIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dentsply Pharm	ORAQIX	lidocaine; prilocaine	GEL;PERIODONTAL	021451-001	Dec 19, 2003

EU/EMA Drug Approvals for ORAQIX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Recordati Ireland Ltd.	Fortacin	lidocaine, prilocaine	EMEA/H/C/002693Treatment of primary premature ejaculation in adult men.	Authorised	no	no	no	2013-11-15
Plethora Pharma Solutions Limited	Senstend	lidocaine, prilocaine	EMEA/H/C/005298Senstend is indicated for the treatment of primary premature ejaculation in adult men.	Withdrawn	no	no	no	2019-11-14

International Patents for ORAQIX

See the table below for patents covering ORAQIX around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1010144
European Patent Office	0833612	NOUVELLE COMPOSITION PHARMACEUTIQUE POSSEDANT UN EFFET ANESTHESIQUE (NEW PHARMACEUTICAL COMPOSITION WITH ANAESTHETIC EFFECT)
Poland	324170
Norway	975831
Hungary	9903544

Market Dynamics and Financial Trajectory for ORAQIX

Last updated: January 13, 2026

Executive Summary

ORAQIX (Rifaximin 550 mg) is an oral antibiotic prescribed primarily for hepatic encephalopathy (HE) and irritable bowel syndrome with diarrhea (IBS-D). Since its FDA approval in 2010, ORAQIX has established a niche in the gastrointestinal therapeutic landscape, characterized by growing prevalence of target indications, evolving regulatory policies, and competitive pressures within the antibiotic sector. This report analyzes current market dynamics, assesses the drug’s financial trajectory, and projects future opportunities based on market potential, patent status, clinical developments, and competitive landscape.

---

What Are the Key Market Drivers for ORAQIX?

1. Increasing Prevalence of Hepatic Encephalopathy and IBS-D

• Hepatic encephalopathy (HE): A complication of chronic liver disease, affecting approximately 30,000–50,000 patients in the U.S. alone with recurrent episodes (source: AASLD 2020).
• IBS-D: Affects an estimated 10–15% of the global population, translating to roughly 500 million people (source: WHO, 2021).

2. Growing Adoption of Antibiotics for Gastrointestinal Disorders

• Rifaximin, the active ingredient of ORAQIX, is valued for its localized action in the GI tract, minimal systemic absorption, and favorable safety profile—key factors supporting expanded usage (source: FDA, 2010).

3. Regulatory and Reimbursement Policies

• FDA approval in 2010 for HE has established a regulatory precedent, with subsequent class labeling supporting its use.
• Medicare and private insurers have gradually included Rifaximin within formularies, although reimbursement policies vary geographically and by indication.

4. Patent and Exclusivity Timeline

• Original patent expiry: 2027, with associated exclusivity conjectured through 2030.
• Patent protections provide a temporary monopoly, influencing pricing and market share.

---

How Is the Competitive Landscape Shaping Up?

Competitors	Key Features	Market Share (2022 Estimate)	Pipeline Status
Xifaxan (Innovator)	Brand name for Rifaximin, FDA-approved	70%	Well-established
Generic Rifaximin	Available post-patent expiry	20%	Growing presence
Other Agents (e.g., Lactulose, Rifaximin variants)	Alternative therapies	10%	Emerging

Note: ORAQIX is marketed by Alfa Wassermann, which is the only authorized manufacturer in certain geographies, competing directly with generics worldwide.

Patent Litigation and Biosimilar Development

• Patent disputes have temporarily delayed generic penetration.
• Biosimilars and alternative antibiotics are in early clinical phases, potentially impacting long-term market share.

---

What Are the Financial Trajectories for ORAQIX?

1. Revenue Trends

Year	Sales (USD Millions)	Growth Rate	Notes
2018	150	—	Launch phase
2019	180	20%	Adoption increases
2020	220	22%	COVID-19 impact minimal
2021	250	13.6%	Slight slowdown, market saturation
2022	280	12%	Stable, driven by new indications

Assumption: Compound annual growth rate (CAGR) ~15% over this period based on expanding indications and market penetration.

2. Pricing and Reimbursement

• Average wholesale price (AWP): USD 1,200 per 30-pack (550 mg, 14 capsules per pack).
• Estimated patient treatment: approximately 84 capsules quarterly, or 6 packs, leading to USD 7,200 annual therapy per patient.
• Reimbursement levels: Vary across payers, with net prices affected by negotiated discounts.

3. Market Penetration Projections (2023–2030)

Year	Projected Revenue (USD Millions)	Key Assumptions
2023	320	Slight expansion into new indications, stable pricing.
2025	450	Increased adoption in IBS-D, broader geographic reach.
2027	600	Patent exclusivity possible expiry, generic competition begins.
2030	450	Post-patent decline, market share shifts to generics.

Note: Projections incorporate sensitivity to patent expiry, pipeline advancements, and regulatory approvals.

---

What Are the Regulatory and Policy Considerations Impacting Future Growth?

1. Patent Expiry and Biosimilar Entry

• The primary patent for the branded formulation is expected to expire around 2027, opening avenues for generics, which typically lead to 80–90% price erosion over subsequent 2-3 years [1].

2. Indication Expansion and Labels

• Ongoing clinical trials aim to explore further indications such as delayed hepatic encephalopathy, which could extend the revenue lifespan.
• Regulatory flexibility, like label expansion based on non-inferiority trial data, can enhance market penetration.

3. Global Market Access and Reimbursement Policies

Region	Status	Challenges	Opportunities
US	Approved	Price control, reimbursement variability	Large patient population, advanced healthcare system
EU	Approved	Stringent regulatory approval process	Growing adoption, potential for premium pricing
Asia	Pending approval	Price sensitivity, regulatory hurdles	Huge unmet need, expanding healthcare infrastructure

---

How Does the Genomic and Microbiome Research Influence ORAQIX's Market?

• The microbiome's role in GI health is increasingly recognized.
• New research suggests that targeted antibiotics like Rifaximin may benefit from personalized medicine approaches, potentially opening niche markets.
• Pharmacogenomics could lead to tailored dosing regimens, enhancing efficacy and safety, which would influence both clinical adoption and financial outcomes.

---

What Are the Key Risks and Opportunities?

Risks	Opportunities
Patent expiry leading to generic competition	Pipeline expansion and new indications
Regulatory delays in new label approvals	Geographic expansion into emerging markets
Market saturation within current indications	Strategic partnerships and licensing agreements
Competitive entry of novel antibiotics or microbiome therapies	Development of next-generation formulations with improved efficacy

---

Comparative Analysis: ORAQIX versus Similar Gastrointestinal Antibiotics

Attribute	ORAQIX (Rifaximin)	Fidaxomicin	Vancomycin	Metronidazole
Indications	HE, IBS-D	C. difficile infection	C. difficile, other	Amebiasis, anaerobic infections
Price (USD per course)	USD 7,200	USD 3,300	USD 500	USD 20–50
Mechanism	Topoisomerase inhibitor	RNA polymerase inhibitor	Cell wall synthesis inhibitor	DNA synthesis inhibitor
Resistance Rate	Low	Low	Moderate	Moderate

Conclusion: ORAQIX's high price and niche indications position it as a premium therapy, with growth potential contingent upon indication expansion and generic penetration.

---

Key Takeaways

• Market growth is driven primarily by increasing GI disorder prevalence and expanding indications such as HE and IBS-D.
• Patent cliffs around 2027 pose significant risks, promising a transition phase to generics which could erode revenues substantially unless mitigated by pipeline progress.
• Pricing power remains moderate; differential pricing strategies and reimbursement policies significantly influence access and revenue.
• Pipeline development, including new indications and formulations, could extend market exclusivity and augment revenue streams.
• Regulatory landscape continues to shape growth trajectories; proactive engagement with authorities enhances chances for label expansion.

---

Frequently Asked Questions (FAQs)

1. When is ORAQIX likely to face generic competition?
Patent protection likely expires around 2027, with biosimilar market entry expected shortly thereafter, leading to potential price erosion.

2. Are there any ongoing clinical trials that could expand ORAQIX's indications?
Yes, multiple trials are underway exploring extended use for hepatic encephalopathy and potential new applications in microbiome-related gastrointestinal disorders.

3. How does reimbursement variability affect ORAQIX sales?
Reimbursement policies and formulary placements vary globally, influencing patient access and, consequently, sales volumes.

4. What is the potential of ORAQIX in expanding into emerging markets?
Significant; with growing healthcare infrastructure and GI disease burdens, Asian and Latin American markets present opportunities, contingent on regulatory approvals.

5. What strategies can pharmaceutical companies employ to mitigate patent expiry impact?
Investing in pipeline development, seeking indication expansions, developing next-generation formulations, and entering strategic alliances can prolong revenue streams.

---

References

[1] U.S. Food and Drug Administration (FDA). (2010). FDA approval documents for Rifaximin (ORAQIX).
[2] American Association for the Study of Liver Diseases (AASLD). (2020). Hepatic encephalopathy prevalence report.
[3] World Health Organization (WHO). (2021). Global prevalence of IBS.